Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer

Cancer

Volumn 117, Issue 2, 2011, Pages 276-282

  Raj, Ganesh V ^a   Karavadia, Saumil ^a   Schlomer, Bruce ^a   Arriaga, Yull ^b   Lotan, Yair ^a   Sagalowsky, Arthur ^a   Frenkel, Eugene ^b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

bladder cancer; chemotherapy; cisplatin; radical cystectomy; utilization

Indexed keywords

CARBOPLATIN; CISPLATIN; CREATININE; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CREATININE CLEARANCE; CYSTECTOMY; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOADJUVANT THERAPY; RECURRENCE; URINARY BLADDER NEOPLASMS;

EID: 78650972192     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25429     Document Type: Article

References (28)

1. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005; 66: 4-34.
2. American Cancer Society Facts and Figures 2008. Atlanta, GA: American Cancer Society, 2008.
3. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. New Engl J Med. 2003; 349: 859-866.
4. Malmstrom PU, Rintala E, Wahlqvist R, et al. Five-year followup of a prospective trial of radical cystectomy, neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol. 1996; 155: 1903-1906.
5. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003; 361: 1927-1934.
6. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005; 48: 202-205; discussion 205-206.
7. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev. 2005; CD005246. doi:10.1002/14651858.CD005246.
8. Cuppone F, Bria E, Carlini P, et al. Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials. Cancer. 2008; 113: 238-246.
9. David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM., Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol. 2007; 178: 451-454.
10. Vaughn DJ., Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium. Cancer Treat Rev. 2008; 34: 328-338.
11. Dogliotti L, Carteni G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007; 52: 134-141.
12. Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer. 1997; 80: 1966-1972.
13. Smith DC, Mackler NJ, Dunn RL, et al. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol. 2008; 180: 2384-2388; discussion 2388.
14. Bellmunt J, Ribas A, Albanell J, et al. M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder. Am J Clin Oncol. 1996; 19: 344-348.
15. Boccardo F, Palmeri L., Adjuvant chemotherapy of bladder cancer. Ann Oncol. 2006; 17 (suppl 5): v129-v132.
16. Calabro F, Sternberg CN., Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2009; 55: 348-358.
17. Gallagher DJ, Bajorin DF., Neoadjuvant chemotherapy for the treatment of muscle-invasive bladder cancer: argument in favor. Nat Clin Prac Urol. 2008; 5: 484-485.
18. Herr HW, Dotan Z, Donat SM, Bajorin DF., Defining optimal therapy for muscle invasive bladder cancer. J Urol. 2007; 177: 437-443.
19. Cohen MH, Rothmann M., Gemcitabine and cisplatin for advanced, metastatic bladder cancer. J Clin Oncol. 2001; 19: 1229-1231.
20. Roberts JT, von der Maase H, Sengelov L, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol. 2006; 17 (suppl 5): v118-v122.
21. Fossa SD, Skovlund E., Selection of patients may limit the generalizability of results from cancer trials. Acta Oncol. 2002; 41: 131-137.
22. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006; 107: 506-513.
23. Raj GV, Iasonos A, Herr H, Donat SM., Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J Clin Oncol. 2006; 24: 3095-3100.
24. Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001; 19: 4005-4013.
25. Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007; 69: 62-79.
26. Donat SM., Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality. J Natl Compr Canc Netw. 2009; 7: 40-47.
27. Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol. 2009; 55: 177-185.
28. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009; 55: 164-174.